NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

ARVN

Arvinas Inc

Jul 03 • 04:00PM ET

7.95

Dollar change +0.05
Percentage change 0.63	%

Healthcare • Biotechnology • USA • NASD

Peers: VRTX IONS EXEL NBIX GILD BMRN REGN ALNY SRPT BIIB

| Held by: VTI IWM VB VXF VBK IWN IBB SCHA VTWO XPH

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-2.08	Insider Own	12.81%	Shs Outstand	73.00M	Perf Week	1.92%
Market Cap	580.28M	Forward P/E	-	EPS next Y	-3.15	Insider Trans	-0.67%	Shs Float	63.64M	Perf Month	13.57%
Enterprise Value	-363.32M	PEG	-	EPS next Q	-0.94	Inst Own	88.81%	Short Float	13.08%	Perf Quarter	10.72%
Income	-149.70M	P/S	3.60	EPS this Y	46.81%	Inst Trans	-9.02%	Short Ratio	3.23	Perf Half Y	-58.16%
Sales	161.00M	P/B	0.88	EPS next Y	-113.69%	ROA	-27.37%	Short Interest	8.33M	Perf YTD	-58.53%
Book/sh	9.04	P/C	0.61	EPS next 5Y	-5.43%	ROE	-60.80%	52W High	34.11 -76.69%	Perf Year	-69.40%
Cash/sh	13.07	P/FCF	-	EPS past 3/5Y	10.20% -5.32%	ROIC	-22.39%	52W Low	5.90 34.75%	Perf 3Y	-81.37%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	70.01% 43.71%	Gross Margin	100.00%	Volatility	5.87% 5.40%	Perf 5Y	-75.09%
Dividend TTM	-	EV/Sales	-2.26	EPS Y/Y TTM	7.38%	Oper. Margin	-230.43%	ATR (14)	0.44	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	4.58	Sales Y/Y TTM	105.10%	Profit Margin	-92.98%	RSI (14)	59.16	Recom	1.95
Dividend Gr. 3/5Y	- -	Current Ratio	4.58	EPS Q/Q	217.81%	SMA20	4.87%	Beta	2.23	Target Price	14.03
Payout	-	Debt/Eq	0.02	Sales Q/Q	646.25%	SMA50	7.24%	Rel Volume	0.32	Prev Close	7.90
Employees	430	LT Debt/Eq	0.01	Earnings	May 01 BMO	SMA200	-51.05%	Avg Volume	2.58M	Price	7.95
IPO	Sep 27, 2018	Option/Short	Yes / Yes	EPS/Sales Surpr.	218.16% 351.18%	Trades		Volume	826,658	Change	0.63%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-02-25	Downgrade	Leerink Partners	Outperform → Market Perform	$9
May-05-25	Downgrade	Truist	Buy → Hold	$11
May-02-25	Downgrade	TD Cowen	Buy → Hold
May-02-25	Downgrade	Jefferies	Buy → Hold	$10
Mar-13-25	Downgrade	Goldman	Buy → Neutral	$70 → $15
Mar-12-25	Downgrade	Wedbush	Outperform → Neutral	$57 → $12
Mar-11-25	Downgrade	Oppenheimer	Outperform → Perform
Dec-10-24	Initiated	BTIG Research	Buy	$69
Nov-18-24	Initiated	Stephens	Overweight	$55
Feb-28-24	Reiterated	Oppenheimer	Outperform	$95 → $80
Feb-14-24	Downgrade	Citigroup	Buy → Neutral	$36 → $55
Feb-01-24	Initiated	Goldman	Buy	$70
Dec-19-23	Upgrade	Wells Fargo	Equal Weight → Overweight	$25 → $63
Dec-06-23	Upgrade	Jefferies	Hold → Buy	$40
Nov-20-23	Upgrade	Guggenheim	Neutral → Buy
Oct-23-23	Upgrade	Wedbush	Neutral → Outperform	$27 → $24
Jun-26-23	Resumed	Oppenheimer	Outperform	$95
Jan-12-23	Downgrade	Guggenheim	Buy → Neutral
Jan-03-23	Downgrade	Wells Fargo	Overweight → Equal Weight	$83 → $49
Sep-09-22	Initiated	Barclays	Overweight	$90

Show Previous Ratings

Jun-16-25 09:55AM	Wall Street Analysts Believe Arvinas (ARVN) Could Rally 89.85%: Here's is How to Trade (Zacks)
Jun-13-25 07:00AM	Arvinas Presents Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at the European Hematology Association 2025 Congress (GlobeNewswire)
Jun-06-25 07:00AM	Arvinas Announces Submission of New Drug Application to U.S. FDA for Vepdegestrant for Patients with ESR1-Mutated ER+/HER2- Advanced or Metastatic Breast Cancer (GlobeNewswire) +8.82%
Jun-05-25 08:28AM	Arvinas to Present Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at the 2025 European Hematology Association (EHA) Annual Meeting (GlobeNewswire)
May-31-25 08:00AM	Arvinas and Pfizer's Vepdegestrant Significantly Improves Progression-Free Survival for Patients with ESR1-Mutant, ER+/HER2- Advanced Breast Cancer (GlobeNewswire)
04:00AM	Loading…
04:00AM	Full Arvinas, Pfizer data confirm potential, limits of Protac drug in breast cancer (BioPharma Dive)
May-30-25 09:55AM	Does Arvinas (ARVN) Have the Potential to Rally 94.93% as Wall Street Analysts Expect? (Zacks)
07:00AM	Arvinas to Present at Jefferies Global Healthcare Conference (GlobeNewswire)
May-29-25 10:29AM	Pfizer and Arvinas gamble to shift breast cancer treatment paradigm (Clinical Trials Arena)
May-28-25 08:00PM	Kirby McInerney LLP is Investigating Potential Shareholder Claims Against Arvinas, Inc. (ARVN) (Business Wire) +8.89%
May-04-25 04:17PM	Arvinas: Yet Another Biotech Trading Below Net Cash, But It's Only A Mild Bull Case (Seeking Alpha)
May-02-25 09:19AM	Here are 1 Main Capital Partners' Views on Arvinas (ARVN) (Insider Monkey) +6.78%
03:03AM	Arvinas Inc (ARVN) Q1 2025 Earnings Call Highlights: Record Revenue Surge and Strategic ... (GuruFocus.com)
May-01-25 09:40PM	Arvinas, Inc. (ARVN) Q1 2025 Earnings Call Transcript (Seeking Alpha) -24.84%
08:15AM	Arvinas, Inc. (ARVN) Q1 Earnings and Revenues Beat Estimates (Zacks)
08:00AM	Loading…
08:00AM	Arvinas, Entrada cut staff; Merck builds US hub for Keytruda (BioPharma Dive)
07:00AM	Arvinas Reports First Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Apr-29-25 10:01AM	Apellis Pharmaceuticals, Inc. (APLS) May Report Negative Earnings: Know the Trend Ahead of Q1 Release (Zacks)
Apr-28-25 07:00AM	Arvinas to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025 (GlobeNewswire)
06:45AM	Arvinas Shares New Preclinical Combination Data for the PROTAC BCL6 Degrader, ARV-393, at the 2025 American Association for Cancer Research Annual Meeting (GlobeNewswire)
Apr-23-25 10:44AM	Arvinas Announces Results from the VERITAC-2 Trial Selected as Late-Breaking Oral Presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire)
Apr-21-25 07:00AM	Arvinas to Present Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at 2025 American Association for Cancer Research (AACR) Annual Meeting (GlobeNewswire)
Apr-09-25 09:43AM	Arvinas, Inc. (ARVN): Among Stocks Under $10 that Will Triple (Insider Monkey) +8.72%
09:35AM	After Plunging -25.42% in 4 Weeks, Here's Why the Trend Might Reverse for Arvinas (ARVN) (Zacks)
Apr-04-25 03:38PM	Arvinas Potential Parkinson's Treatment Shows Positive Data In Human Study (Benzinga)
12:33PM	Arvinas PROTAC halves protein suspected to play role in Parkinsons (Clinical Trials Arena)
07:00AM	Arvinas Presents First-in-Human Data for Investigational Oral PROTAC ARV-102 Demonstrating Blood-Brain Barrier Penetration, and Central and Peripheral LRRK2 Degradation (GlobeNewswire)
Mar-27-25 07:00AM	Arvinas Announces Oral Presentation at 2025 International Conference on Alzheimer's & Parkinson's Diseases (GlobeNewswire)
Mar-21-25 12:44PM	OPTN Stock Soars 53% on Inking $330M Deal to be Acquired by Paratek (Zacks)
12:37PM	Mirum's Heavy Dependence on Livmarli for Revenues Remains a Woe (Zacks)
12:17PM	Loading…
12:17PM	PSTV Stock Surges as FDA Accepts Proprietary Name for Lead Drug (Zacks)
09:26AM	ESPR to Study Bempedoic Acid in Pediatric Familial Hypercholesterolemia (Zacks)
Mar-20-25 10:19AM	IMVT Unlikely to Pursue Batoclimab for MG & CIDP Despite Success (Zacks)
Mar-19-25 10:59AM	JNJ's Nipocalimab Gets FDA's Fast Track Tag for Sjogren's Disease (Zacks)
09:35AM	Down -54.85% in 4 Weeks, Here's Why Arvinas (ARVN) Looks Ripe for a Turnaround (Zacks)
Mar-18-25 08:05PM	Is Arvinas, Inc. (ARVN) a Pump and Dump Stock Favored by Hedge Funds? (Insider Monkey)
Mar-17-25 09:35AM	Down -53.96% in 4 Weeks, Here's Why Arvinas (ARVN) Looks Ripe for a Turnaround (Zacks)
Mar-14-25 12:15PM	Biotech Alert: Searches spiking for these stocks today (TipRanks)
Mar-13-25 10:52AM	Arvinas (ARVN) Moves 8.8% Higher: Will This Strength Last? (Zacks) -5.32%
Mar-11-25 04:06PM	Arvinas Plummets 53% On Mixed Results For Its Pfizer-Tied Breast Cancer Drug (Investor's Business Daily) -52.73% +8.80%
11:43AM	Pfizer and Arvinass HER2-breast cancer drug extends PFS in certain patients (Clinical Trials Arena)
07:45AM	Arvinas gets positive breast cancer data, but finds differentiation a hard sell (BioPharma Dive)
06:45AM	Arvinas and Pfizer Announce Positive Topline Results from Phase 3 VERITAC-2 Clinical Trial (GlobeNewswire)
Mar-04-25 04:05PM	Arvinas to Participate in Upcoming Investor Conferences (GlobeNewswire) +5.90%
Mar-03-25 09:55AM	Wall Street Analysts Predict a 228.87% Upside in Arvinas (ARVN): Here's What You Should Know (Zacks) -8.31%
Feb-14-25 12:00PM	All You Need to Know About Arvinas (ARVN) Rating Upgrade to Buy (Zacks)
09:55AM	How Much Upside is Left in Arvinas (ARVN)? Wall Street Analysts Think 235.09% (Zacks)
Feb-12-25 02:49AM	Q4 2024 Arvinas Inc Earnings Call (Thomson Reuters StreetEvents)
02:06AM	Arvinas Inc (ARVN) Q4 2024 Earnings Call Highlights: Strong Financial Position and Promising ... (GuruFocus.com)
Feb-11-25 08:15AM	Arvinas, Inc. (ARVN) Reports Q4 Loss, Misses Revenue Estimates (Zacks) -6.80%
07:00AM	Arvinas Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Feb-10-25 07:17AM	What To Expect From Arvinas Inc (ARVN) Q4 2024 Earnings (GuruFocus.com)
Feb-03-25 07:00AM	Arvinas to Report Fourth Quarter and Full Year 2024 Financial Results on Tuesday, February 11, 2025 (GlobeNewswire)
Jan-21-25 04:29AM	2 Growth Stocks That Could Rocket Higher in the First Quarter of 2025 (Motley Fool)
Jan-10-25 07:00AM	Arvinas Updates Guidance for First- and Second-Line Phase 3 Combination Trials with Vepdegestrant, Highlights Upcoming Milestones, and Provides Corporate Update (GlobeNewswire) -6.05%
Dec-11-24 05:38AM	Arvinas and Pfizers combo therapy shows promise in breast cancer trial (Clinical Trials Arena) -8.34%
Dec-10-24 01:23PM	Arvinas-Pfizer Partner Cancer Drug Trial Shows 63% Clinical Benefit In Breast Cancer Patients (Benzinga)
09:05AM	Arvinas and Pfizer Announce Initial Phase 1b Data from the TACTIVE-U Sub-Study of Vepdegestrant in Combination with Abemaciclib at 2024 San Antonio Breast Cancer Symposium (GlobeNewswire)
Dec-04-24 01:19PM	Why Is Arvinas, Inc. (ARVN) Among the Best Small-Cap Biotech Stocks With Massive Potential According to Hedge Funds? (Insider Monkey)
Nov-27-24 07:00AM	Arvinas to Present at Piper Sandler 36th Annual Healthcare Conference (GlobeNewswire) +6.13%
Nov-25-24 05:35PM	Arvinas Announces Upcoming Vepdegestrant Poster Presentations at the 2024 San Antonio Breast Cancer Symposium (GlobeNewswire)
Nov-19-24 09:06AM	Arvinas, Inc. (ARVN): This Small-Cap Stock Is Ready To Explode (Insider Monkey) -6.68%
Nov-04-24 07:00AM	Arvinas to Participate in Upcoming Investor Conferences (GlobeNewswire)
Oct-31-24 03:05AM	Arvinas Inc (ARVN) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Promising ... (GuruFocus.com)
Oct-30-24 08:10AM	Arvinas, Inc. (ARVN) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
07:00AM	Arvinas Reports Third Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Oct-29-24 09:10AM	Arvinas Inc (ARVN) Q3 2024: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
Oct-23-24 08:44AM	Arvinas (ARVN): A Small-Cap Biotech with High Growth Potential (Insider Monkey)
Oct-22-24 04:05PM	Arvinas Gives Back to Local Greater New Haven Community in Third Annual Impact Day (GlobeNewswire)
Oct-21-24 07:00AM	Arvinas to Report Third Quarter 2024 Financial Results and Provide Corporate Update and Host Webcast on Wednesday, October 30, 2024 (GlobeNewswire)
Sep-12-24 01:18AM	Vanguard Group Inc's Strategic Acquisition of Arvinas Inc Shares (GuruFocus.com)
Sep-05-24 12:01AM	Arvinas, Inc. (ARVN): This Small-Cap Healthcare Stock Is A Good Buy Right Now (Insider Monkey)
Sep-02-24 05:22PM	10 Best Small-Cap Healthcare Stocks To Buy Now (Insider Monkey)
Aug-29-24 07:00AM	Arvinas to Participate in Upcoming Investor Conferences (GlobeNewswire)
Jul-30-24 01:53PM	ARVN Stock Earnings: Arvinas Beats EPS, Beats Revenue for Q2 2024 (InvestorPlace)
08:20AM	Arvinas, Inc. (ARVN) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
07:00AM	Arvinas Reports Second Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Jul-22-24 08:30AM	HOOKIPA Pharma Announces Leadership Changes to Intensify Focus on HB-200 (GlobeNewswire)
Jul-17-24 03:06PM	Biotech Arvinas Stock Earns 82 RS Rating (Investor's Business Daily)
08:44AM	Arvinas (ARVN) Surges 9.2%: Is This an Indication of Further Gains? (Zacks)
Jul-15-24 08:00AM	Milestone Pharmaceuticals Refreshes Board of Directors (GlobeNewswire)
Jun-27-24 09:31AM	Arvinas, Inc. (ARVN): Why Did Analysts Give This Small-Cap Stock a Strong Buy Rating? (Insider Monkey)
Jun-26-24 04:36PM	Top 10 Small-Cap Stocks with Highest Upside Potential (Insider Monkey) +5.76%
Jun-24-24 04:37PM	Arvinas Appoints Andrew Saik as Chief Financial Officer and Treasurer (GlobeNewswire)
Jun-21-24 07:00AM	Arvinas Announces Presentations for Two of its PROTAC® Investigational Programs Targeting BCL6 and LRRK2 (GlobeNewswire)
Jun-17-24 07:00AM	Arvinas Announces Promotions of Ian Taylor, Ph.D. to President of Research and Development and Angela Cacace, Ph.D. to Chief Scientific Officer (GlobeNewswire)
Jun-03-24 04:30PM	Arvinas to Participate in Upcoming Investor Conferences (GlobeNewswire) -15.84%
May-23-24 05:00PM	Arvinas Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual Congress (GlobeNewswire)
May-16-24 09:10AM	Sector Update: Health Care Stocks Steady Premarket Thursday (MT Newswires)
08:07AM	Correction: Arvinas, Pfizer Breast Cancer Treatment Shows 'Encouraging' Clinical Activity (MT Newswires)
07:01AM	Arvinas, Pfizer Breast Cancer Treatment Shows 'Encouraging' Clinical Activity (MT Newswires)
06:00AM	Arvinas and Pfizer Announce Updated Clinical Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE) (GlobeNewswire)
May-09-24 04:42PM	Arvinas Announces Upcoming Vepdegestrant Poster Presentations at the 2024 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress (GlobeNewswire)
May-08-24 08:36AM	Oppenheimer Adjusts Arvinas Price Target to $70 From $80, Maintains Outperform Rating (MT Newswires) -5.71%
May-07-24 01:54PM	ARVN Stock Earnings: Arvinas Beats EPS, Misses Revenue for Q1 2024 (InvestorPlace) +6.42%
10:27AM	Arvinas Shares Up After Q1 Net Loss Narrows (MT Newswires)
08:15AM	Arvinas, Inc. (ARVN) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
07:00AM	Arvinas Reports First Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
May-02-24 10:00AM	Why Earnings Season Could Be Great for Arvinas (ARVN) (Zacks)
07:00AM	Arvinas to Present at Upcoming Investor Conferences (GlobeNewswire)

Arvinas, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its product candidates are ARV-110, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer, ARV-471, and ARV-766, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer. The company was founded in February 2013 and is headquartered in New Haven, CT.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Saik Andrew	Chief Financial Officer	Jun 24 '25	Sale	7.61	5,700	43,377	164,401	Jun 24 04:08 PM
Andrew Saik	Officer	Jun 24 '25	Proposed Sale	7.35	5,927	43,593		Jun 23 04:13 PM
Cacace Angela M	Chief Scientific Officer	Jun 17 '25	Sale	7.49	2,583	19,347	154,248	Jun 18 06:04 PM
Berkowitz Noah	Chief Medical Officer	Mar 18 '25	Sale	8.59	8,658	74,372	110,023	Mar 19 08:06 AM
Noah Berkowitz	Officer	Mar 18 '25	Proposed Sale	8.59	8,658	74,372		Mar 18 09:50 PM
Loomis David K	Chief Accounting Officer	Feb 24 '25	Sale	16.75	1,214	20,334	18,863	Feb 25 06:37 AM
Cacace Angela M	Chief Scientific Officer	Feb 24 '25	Sale	16.70	4,207	70,238	97,231	Feb 25 06:35 AM
Taylor Ian	President, R&D	Feb 24 '25	Sale	16.71	9,020	150,752	159,121	Feb 25 06:33 AM
Houston John G	President and CEO	Feb 24 '25	Sale	16.72	31,338	523,881	1,157,480	Feb 25 06:31 AM
Ian Taylor	Officer	Feb 24 '25	Proposed Sale	16.71	9,020	150,730		Feb 24 08:50 PM
John G Houston	Officer	Feb 24 '25	Proposed Sale	16.71	31,338	523,801		Feb 24 08:48 PM
Angela M Cacace	Officer	Feb 24 '25	Proposed Sale	16.69	4,207	70,230		Feb 24 08:46 PM
Loomis David K	Chief Accounting Officer	Nov 07 '24	Sale	27.69	231	6,396	8,040	Nov 12 05:34 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ARVN

Arvinas Inc

Upgrade your FINVIZ experience